UNH
Earnings were good. The after-party was better.
UnitedHealth didn’t just beat first-quarter expectations — it did the classic “beat, raise, repeat” routine that gets analysts reaching for the red pen. Q1 adjusted EPS came in at $7.23, ahead of the $6.58 consensus, while revenue hit $111.7 billion and also cleared the Street’s bar.
Then came the part investors really love: management nudged its full-year 2026 adjusted EPS outlook up to greater than $18.25 from greater than $17.75. In plain English, the company is saying the year looks a little sturdier than Wall Street feared. That’s the kind of line that makes sell-side models twitch like they’ve had too much coffee.
The analyst chorus got louder
A bunch of firms responded by lifting price targets:
- Truist Securities kept a Buy and raised its target from $370 to $395
- Barclays stuck with Overweight and moved its target from $327 to $373
- Baird stayed Underperform but still nudged its target from $278 to $287
- Oppenheimer kept Outperform and lifted its target from $385 to $405
That mix is the funny part: even the cautious camp is inching higher. When the pessimists start raising numbers, it’s usually because the business is doing something right.
Why you should care
UnitedHealth is a giant in managed care, so when it flexes on earnings, it can move the whole health-insurance conversation with it. Shares were up 2.8% to $355.51, and the message from analysts was basically: “Yeah, the stock already moved — but maybe not enough.”
Big picture: if UNH can keep utilization in check and deliver on that higher profit outlook, this could stay one of those boring-looking stocks that quietly keeps winning.